Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma.
Vogt A, Sadeghlar F, Ayub TH, Schneider C, Möhring C, Zhou T, Mahn R, Bartels A, Praktiknjo M, Kornek MT, Toma M, Schmidt-Wolf IGH, Branchi V, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Vogt A, et al. Among authors: bartels a. Cancers (Basel). 2021 Jul 5;13(13):3375. doi: 10.3390/cancers13133375. Cancers (Basel). 2021. PMID: 34282787 Free PMC article.
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.
Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Gonzalez-Carmona MA, et al. Among authors: bartels a. Sci Rep. 2022 Jan 19;12(1):1011. doi: 10.1038/s41598-021-04297-2. Sci Rep. 2022. PMID: 35046437 Free PMC article.
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis.
Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: bartels a. Front Oncol. 2021 Nov 10;11:717397. doi: 10.3389/fonc.2021.717397. eCollection 2021. Front Oncol. 2021. PMID: 34858809 Free PMC article.
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C, Frontado Graffe FJ, Bartels A, Sadeghlar F, Zhou T, Mahn R, Marinova M, Feldmann G, Brossart P, Glowka TR, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: bartels a. J Gastrointest Oncol. 2023 Feb 28;14(1):352-365. doi: 10.21037/jgo-22-632. Epub 2023 Feb 15. J Gastrointest Oncol. 2023. PMID: 36915455 Free PMC article.
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Möhring C, Timotheou A, Mańczak A, Sadeghlar F, Zhou T, Mahn R, Bartels A, Monin M, Toma M, Feldmann G, Brossart P, Köksal M, Sarria GR, Giordano FA, Lingohr P, Jafari A, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: bartels a. J Cancer Res Clin Oncol. 2023 May;149(5):1849-1862. doi: 10.1007/s00432-022-04109-8. Epub 2022 Jun 28. J Cancer Res Clin Oncol. 2023. PMID: 35763109
Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes.
Mahn R, Sadeghlar F, Bartels A, Zhou T, Weismüller T, Kupczyk P, Meyer C, Gaertner FC, Toma M, Vilz T, Knipper P, Glowka T, Manekeller S, Kalff J, Strassburg CP, Gonzalez-Carmona MA. Mahn R, et al. Among authors: bartels a. Medicine (Baltimore). 2021 Sep 24;100(38):e27082. doi: 10.1097/MD.0000000000027082. Medicine (Baltimore). 2021. PMID: 34559100 Free PMC article.